South Dakota Investment Council Supernus Pharmaceuticals, Inc. Transaction History

South Dakota Investment Council

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$23.54 - $31.39 $70,408 - $93,887	-2,991 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$26.72 - $33.19 $2.63 Million - $3.27 Million	-98,420 Reduced 97.05%	2,991 $92,000
Q1 2021 May 13, 2021	BUY	$24.15 - $31.45 $8,066 - $10,504	334 Added 0.33%	101,411 $2.66 Million
Q3 2020 Nov 06, 2020	SELL	$20.2 - $25.05 $230,684 - $286,071	-11,420 Reduced 10.15%	101,077 $2.11 Million
Q1 2020 May 11, 2020	SELL	$14.45 - $24.69 $1,488 - $2,543	-103 Reduced 0.09%	112,497 $2.02 Million
Q4 2019 Feb 11, 2020	SELL	$19.93 - $29.13 $33,881 - $49,521	-1,700 Reduced 1.49%	112,600 $2.67 Million
Q3 2019 Nov 13, 2019	BUY	$25.47 - $33.37 $962,766 - $1.26 Million	37,800 Added 49.41%	114,300 $3.14 Million
Q2 2019 Aug 13, 2019	BUY	$29.96 - $38.87 $317,576 - $412,022	10,600 Added 16.08%	76,500 $2.53 Million
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $12,810 - $16,965	300 Added 0.46%	65,900 $3.32 Million
Q1 2018 May 10, 2018	BUY	$37.15 - $46.9 $2.44 Million - $3.08 Million	65,600 New	65,600 $3 Million

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.9B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of South Dakota Investment Council, based on Form 13F filings with the SEC.

Stay updated on South Dakota Investment Council with notifications on news.